Pharmaceuticals

Inhalable Biologics Market Forecast: How Big Will It Be by 2030?

February 16, 2026March 11, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the inhalable biologics market from 2026–2035 with trusted insights from The Business Research Company

What total market size is anticipated for the Inhalable Biologics Market in 2030?

The inhalable biologics market has experienced rapid expansion in recent years. It is anticipated to grow from $3.22 billion in 2025 to $3.73 billion in 2026, achieving a compound annual growth rate (CAGR) of 15.7%. The expansion observed in the historic period can be attributed to several factors including the rising prevalence of respiratory diseases, limitations of injectable biologics, advances in inhalation device technology, a growing biologics pipeline, and increasing hospital-based respiratory care.

The inhalable biologics market is projected to experience substantial expansion in the coming years. This market is predicted to reach $6.67 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 15.6%. This projected growth during the forecast period is largely driven by factors such as the rise in chronic respiratory conditions, the broadening application of inhalable biologics beyond respiratory uses, a growing patient inclination for non-invasive treatments, progress in formulation stability, and increased funding for pulmonary drug delivery research. Significant trends anticipated for the forecast period include the widening of pulmonary delivery for systemic biologics, an increase in the utilization of dry powder inhalers for biologics, an intensified focus on targeted lung drug delivery, the rising development of inhalable monoclonal antibodies, and the widespread adoption of patient-friendly non-invasive biologic therapies.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24253&type=smp

What Drivers Are Influencing Production Trends In The Inhalable Biologics Market?

The escalating prevalence of respiratory conditions is anticipated to drive the growth of the inhalable biologics market moving forward. Respiratory conditions encompass diseases and disorders that affect the lungs and other parts of the respiratory system, including airways, nasal passages, and the lungs themselves. The widespread occurrence of these conditions is linked to increasing air pollution, which exacerbates issues such as asthma, chronic obstructive pulmonary disease (COPD), and lung cancer by exposing individuals to harmful particulate matter and other environmental pollutants. Inhalable biologics prove beneficial for respiratory conditions by delivering targeted treatment directly to the lungs, effectively reducing inflammation and improving lung function with fewer systemic side effects. For instance, in June 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, in 2023, COPD accounted for 3.6% of the total disease burden and 50% of the respiratory disease burden. Thus, the increasing incidence of respiratory conditions significantly contributes to the expansion of the inhalable biologics market.

Which Segments Are Gaining Traction In The Inhalable Biologics Market?

The inhalable biologics market covered in this report is segmented –

1) By Type: Peptides And Proteins, Vaccines, Monoclonal Antibodies, RNAi-Based Therapeutics, Other Types

2) By Dosage Form: Dry Powder Inhalers, Metered Dose Inhalers, Nebulizers, Other Dosage Forms

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

4) By Application: Respiratory Diseases, Diabetes, Cancer, Other Applications

Subsegments:

1) By Peptides And Proteins: Insulin, Growth Hormones, Enzyme Replacement Therapies, Other Peptides And Proteins

2) By Vaccines: Influenza Vaccines, Other Respiratory Vaccines

3) By Monoclonal Antibodies: Respiratory Monoclonal Antibodies, Immunomodulatory Monoclonal Antibodies, Other Monoclonal Antibodies

4) By RNAi-Based Therapeutics: RNA-Based Drugs For Respiratory Diseases, Other RNAi-Based Therapeutics

5) By Other Types: Gene Therapies, Small Molecule Inhalable Drugs, Other Innovative Inhalable Biologics

Which Competitive Trends Are Impacting The Structure Of The Inhalable Biologics Market?

Leading companies in the inhalable biologics market are concentrating on developing innovative solutions, such as inhaled insulin, to improve patient compliance and achieve rapid glycemic control. Inhaled insulin is a type of insulin delivered into the bloodstream through the lungs via inhalation, rather than through injections or insulin pumps. This method involves inhaling a powdered or aerosolized form of insulin, which is absorbed through the lungs and quickly enters the bloodstream to help regulate blood sugar levels. For instance, in February 2025, Cipla Limited, an India-based pharmaceutical company, received regulatory approval from the Central Drugs Standard Control Organization for Afrezza, the world’s fastest inhaled insulin, offering a revolutionary, needle-free option for adults with type 1 and type 2 diabetes. This ultra-rapid-acting insulin becomes effective within 12 to 15 minutes of inhalation, closely mimicking the natural insulin response to meals and improving blood sugar management. The inhaled insulin provides a more comfortable alternative to multiple daily injections, particularly benefiting patients with injection anxiety and enhancing adherence to insulin therapy.

Who Are The Prominent Global Companies Shaping The Inhalable Biologics Market Landscape?

Major companies operating in the inhalable biologics market are Bayer AG, Sanofi SA, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Moderna Inc., Pfizer Inc. and BioNTech SE, Teva Pharmaceuticals, Baxter International, Lonza Group AG, CanSino Biologics Inc., Cipla Ltd., Insmed Incorporated, Kamada Pharmaceuticals, Vectura Group plc, F. Hoffmann-La Roche Ltd, Iconovo AB, Synairgen plc, Ab Initio Pharma LLC, Nanopharm Ltd, Ocugen Inc., MannKind Corporation

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/inhalable-biologics-global-market-report

Which Geographic Areas Are Emerging As Strong Markets For The Inhalable Biologics Market?

North America was the largest region in the inhalable biologics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inhalable biologics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Inhalable Biologics Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24253&type=smp

Browse Through More Reports Similar to the Global Inhalable Biologics Market 2026, By The Business Research Company

Inhalable Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/inhalable-drugs-global-market-report

Inhalation Cdmo Market Report 2026

https://www.thebusinessresearchcompany.com/report/inhalation-cdmo-global-market-report

Inhalation Anesthesia Market Report 2026

https://www.thebusinessresearchcompany.com/report/inhalation-anesthesia-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795